Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial

No abstract is available for this paper.

• Publication year

  2000

• Venue

  British medical journal

• Publication date

  2000-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/bmj.321.7252.13PMID 10875825PMCID PMC27417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• British Hypertension Society guidelines for hypertension management 1999: summary

  1999cited by this paper
• Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.

  1999cited by this paper
• Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework.

  1998cited by this paper
• Individualizing aspirin therapy for prevention of cardiovascular events.

  1998cited by this paper
• Antithrombotic agents in coronary artery disease.

  1998cited by this paper
• Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

  1998cited by this paper
• Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk

  1998cited by this paper
• Prophylactic aspirin and risk of peptic ulcer bleeding

  1995cited by this paper
• Does aspirin consumption affect the presentation or severity of acute myocardial infarction?

  1995cited by this paper
• Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes.

  1995cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

  1994cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

  1994cited by this paper
• Coronary heart disease case fatality in four countries. A community study. The Acute Myocardial Infarction Register Teams of Auckland, Augsburg, Bremen, FINMONICA, Newcastle, and Perth.

  1993cited by this paper
• Coronary Heart Disease Case Fatalit in Four Countries A Community Study

  1993cited by this paper
• Extra-Cranial Bleeding and Other Symptoms due to Low Dose Aspirin and Low Intensity Oral Anticoagulation

  1992cited by this paper
• Final report on the aspirin component of the ongoing Physicians' Health Study.

  1989cited by this paper
• Antithrombotic agents in coronary artery disease.

  1989cited by this paper
• Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study.

  1988cited by this paper
• Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.

  1986cited by this paper

• Aspirin Resistance and Ischemic Stroke

  2024cites this paper
• Antiplatelet agents and anticoagulants for hypertension.

  2022cites this paper
• Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer Updated Evidence Report and Systematic Review for the US Preventive Services Task Force

  2022cites this paper
• Meta-Analysis of Aspirin for Primary Prevention of Stroke

  2022cites this paper
• Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

  2022cites this paper
• Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological study

  2019cites this paper
• An aspirin a day? Clinical utility of aspirin therapy for the primary prevention of cardiovascular disease

  2019cites this paper
• Reply.

  2019cites this paper
• Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks

  2019cites this paper
• Aspirin resistance in patients with ischemic stroke

  2018cites this paper
• Efficacy of aspirin and statins in primary prevention of cardiovascular mortality in uncomplicated hypertensive participants: a Korean national cohort study

  2017cites this paper
• Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios Grupo de Trabajo sobre el uso de agentes antiplaquetarios en pacientes con enfermedad cardiovascular aterosclerótica de la Sociedad Europea de Cardiología

  2016cites this paper
• The Benefit and Safety of Aspirin for Primary Prevention of Ischemic Stroke: A Meta-Analysis of Randomized Trials

  2016influential citation
• Outcome Measures

  2016cites this paper
• Prévalence des porteurs de plaques d’athérome carotidiennes dans la population semi-rurale de Guéoul au Sénégal : enquête sur 1411 sujets

  2016cites this paper
• [Prevalence of atherosclerotic carotid plaques in semi-rural Gueoul, Senegal: Survey of 1411 subjects].

  2016cites this paper
• Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force

  2016cites this paper
• Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms

  2015cites this paper
• Aspirin non-responder in Thai ischemic stroke patients.

  2013cites this paper
• The contribution of platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2G-765C) polymorphisms to platelet response in patients treated with aspirin.

  2013cites this paper
• Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. Part II: Potential causes and laboratory tests.

  2013cites this paper
• Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.

  2012cites this paper
• Approaches to Prevention of Cardiovascular Complications and Events in Diabetes Mellitus

  2012cites this paper
• Aspirin in Type 2 Diabetes: A survey of prescribing habits and Investigation of effects on Inflammation, Oxidative stress, Insulin Resistance and Endothelial Function.

  2012cites this paper
• The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin

  2012cites this paper
• Antiplatelet Agents

  2012cites this paper
• 60 – Conduct of Stroke-Related Clinical Trials

  2011cites this paper
• Peri-operative management of antiplatelet therapy in patients with coronary artery disease

  2011cites this paper
• Antiplatelet agents and anticoagulants for hypertension.

  2011cites this paper
• Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy

  2011cites this paper
• The Role of Antiplatelets in Hypertension and Diabetes Mellitus

  2011cites this paper
• Platelet activation in essential hypertension: implications for antiplatelet treatment.

  2010cites this paper
• CHAPTER 43 – Hypertension

  2010cites this paper
• [Antithrombotic therapy in patients with prosthetic heart valves].

  2010cites this paper
• Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control

  2009cites this paper
• Diabetes, vascular complications and antiplatelet therapy: open problems

  2009cites this paper
• Clinical Applications of Aspirin

  2009cites this paper
• Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control.

  2009cites this paper
• Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics

  2009cites this paper
• [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].

  2008cites this paper
• Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate.

  2008cites this paper
• Diagnostic efficacy for coronary in-stent patency with parameters defined on Hounsfield CT value-spatial profile curves

  2008cites this paper
• Does the level of prostate cancer risk affect cancer prevention with finasteride?

  2008cites this paper
• Aspirin for the Primary Prevention of Adverse Cardiovascular Events

  2008cites this paper
• Papel do ácido acetilsalicílico na prevenção primária cardiovascular. Revisão baseada na evidência

  2007cites this paper
• Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100

  2007cites this paper
• Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management

  2007cites this paper
• The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome.

  2007cites this paper
• Diabetes care for patients with peripheral arterial disease.

  2007cites this paper
• Outcomes of patients who participate in randomised controlled trials compared to similar patients receiving similar interventions who do not participate.

  2007cites this paper
• Aspirin and Antiplatelet Drugs in the Prevention of Cardiovascular Complications of Diabetes

  2007cites this paper
• CHAPTER 60 – Aspirin

  2007cites this paper
• Pharmacotherapy of Diabetes

  2007cites this paper
• Chapter 89 – Antithrombotic Therapy in Hypertension

  2007cites this paper
• Individual variation in in vitro efficacy of antiplatelet medication - aspirin and clopidogrel

  2007cites this paper
• The impact of low‐dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non‐selective non‐steroidal anti‐inflammatory drug or a cyclo‐oxygenase‐2‐selective inhibitor

  2006cites this paper
• Antithrombotic therapy: standard therapy in essential hypertension?

  2006cites this paper
• Prevención de la enfermedad cardiovascular con aspirina: resumen de la evidencia y la calidad de la prescripción en Argentina

  2006cites this paper
• Stanowisko Europejskiego Towarzystwa Kardiologicznego

  2006cites this paper
• Review: Aspirin and diabetes

  2006cites this paper
• Aspirin resistance in stroke: 2004.

  2005cites this paper
• Aspirin for the primary prevention of cardiovascular disease a comprehensive review

  2005cites this paper
• PLATELET FUNCTION IN DIABETES MELLITUS

  2005cites this paper
• Aspirin Under Fire: Aspirin Use in the Primary Prevention of Coronary Heart Disease

  2005cites this paper
• Recommendations for the management of patients after heart valve surgery.

  2005cites this paper
• Aspirin and Cardiovascular Prevention in the Guidelines and in the Real World

  2005cites this paper
• Antithrombotic therapy in hypertension: a Cochrane Systematic review

  2005cites this paper
• Aspirin resistance

  2005cites this paper
• Primäre Prävention kardiovaskulärer Erkrankungen mit Acetylsalicylsäure

  2005cites this paper
• Aspirin resistance.

  2005cites this paper
• [Primary prevention of cardiovascular diseases with acetylsalicylic acid].

  2005cites this paper
• Should Hypertensive Patients Take Aspirin? A Report from the Food and Drug Administration

  2004cites this paper
• Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin

  2004cites this paper
• Antiplatelet Agents for the Prevention of Cardiovascular Disease in Diabetes Mellitus

  2004cites this paper
• Aspirin resistance in diabetic patients.

  2004cites this paper
• Under-diagnosis of diabetes mellitus in patients with coronary artery disease.

  2004cites this paper
• Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios

  2004cites this paper
• Prävention der koronaren Herzerkrankung

  2004cites this paper
• Aspirin Resistance in Diabetic Patients Response to Sacco et al.

  2004cites this paper
• Conduct of Stroke-Related Clinical Trials

  2004cites this paper
• Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.

  2004cites this paper
• [Expert consensus document on the use of antiplatelet agents].

  2004cites this paper
• Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.

  2003influential citation
• Prophylactic aspirin use in the adult general population.

  2003cites this paper
• Primary prevention of cardiovascular diseases

  2003cites this paper
• Aspirin for the Prevention of Cardiovascular Events in the Elderly

  2003cites this paper
• Actualización (2003) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en hipertensión arterial

  2003cites this paper
• Kardiologie 2001/2002 – Teil I¶Vom Risikofaktor zur symptomatischen koronaren Herzkrankheit

  2003cites this paper
• Low-Dose Aspirin for Primary Prevention of Cardiovascular Disease

  2003cites this paper
• Who should be taking aspirin to prevent coronary events?

  2003cites this paper
• Selección de medicamentos en el anciano (II): recomendaciones específicas en las enfermedades más relevantes

  2003cites this paper
• [2003 update of the Guidelines of the Spanish Society of Cardiology on High Blood Pressure].

  2003cites this paper
• [From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].

  2003cites this paper
• Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk

  2002cites this paper
• [Aspirin in the primary prevention of the hypertensive patient].

  2002cites this paper
• Nontraumatic exercise-related deaths in the U.S. military, 1996-1999.

  2002cites this paper
• A SPIRIN FOR P RIMARY P REVENTION OF C ORONARY E VENTS

  2002cites this paper
• Aspirina en la prevención primaria del paciente hipertenso

  2002cites this paper
• Primary prevention of diseases of old age

  2002cites this paper
• Clinical practice. Aspirin for primary prevention of coronary events.

  2002cites this paper